Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
G P SuttonJ H Malfetano

Abstract

Ifosfamide (isophosphamide) and mesna (2-mercaptoethane sodium sulfonate) were administered intravenously at monthly intervals to 46 patients with advanced epithelial ovarian carcinoma refractory to or recurrent after cisplatin-containing combination chemotherapy. Initially, ifosfamide was given as 1.5 g/m2/d x 5 days and mesna as 300 mg/m2 every 4 hours for three doses following ifosfamide, but the initial dose of ifosfamide was reduced to 1.2 g/m2 because of toxicity. Four of the patients initially entered were found to be ineligible: two who had had more than one prior chemotherapy regimen and two who did not have ovarian primaries. One patient received an inadequate trial and four patients had discontinuation of therapy because of toxicity, leaving 41 evaluable for response. Three patients (7.0%) had complete responses and five (13.0%) had partial responses for an overall response rate of 20.0%. Response duration ranged from 2.1 to 20.3 + months with a median of 6.9 + months. Two patients died of renal failure, one of whom had no known renal disease and received 1.5 g/m2/d x 5 days ifosfamide. The second patient received the 1.2 g/m2 dose and was found to have chronic pyelonephritis and pyonephrosis at autopsy. Gynecologic ...Continue Reading

Citations

Jan 1, 1991·Journal of Cancer Research and Clinical Oncology·A D EliasE Frei
Oct 8, 1999·Journal of the National Cancer Institute·J E Groopman, L M Itri
Mar 8, 2000·The Oncologist·M Markman, M A Bookman
Aug 10, 2000·Drugs & Aging·R E van Rijswijk, J B Vermorken
Oct 13, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Mauro SignorelliNicoletta Colombo
Jan 1, 1991·Journal of Cancer Research and Clinical Oncology·W P BradeC E Araujo
Jul 16, 1992·The New England Journal of Medicine·C O Granai
Jan 1, 1992·Cancer Investigation·R J Schilder, R F Ozols
Nov 18, 1993·The New England Journal of Medicine·S A Cannistra
Jul 1, 1991·Cancer·N R Anderson, D S Tandon
Jul 23, 1998·Australian and New Zealand Journal of Medicine·Z AzizT Arshad
Mar 20, 2003·Cancer Investigation·Abbie L Fields, Carolyn D Runowicz
Aug 7, 2003·American Journal of Clinical Oncology·Süleyman AliciErkan Topuz
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C DoyleA M Oza
Feb 1, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·F JolyJ F Heron
Jun 1, 2004·American Journal of Clinical Oncology·Montaser ShaheenLawrence H Einhorn
Jan 1, 1992·Hematological Oncology·R F Ozols
Dec 21, 2000·Current Oncology Reports·A A Garcia
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A N GordonA J Lacave
Apr 29, 2014·World Journal of Microbiology & Biotechnology·Míria Benetati Delgado BertéliNelson Barros Colauto
Aug 6, 2013·Cancer Chemotherapy and Pharmacology·Taejong SongDuk Soo Bae
Apr 3, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M GoreS Z Fields
Dec 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A Di LeoS Oriana

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.